Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp
OPKO Health (OPK) agreed to sell select BioReference Health assets to Labcorp for $722M+ in cash, with a potential $150M earnout. The deal, subject to regulatory approval, includes clinical and women's health testing services and over 80 patient service centers. According to OPKO, the price may adjust based on closing revenues.
How this was made
The 30-second read
Why it matters
The deal provides OPKO with immediate liquidity and Labcorp with expanded testing capabilities, potentially reshaping competitive dynamics in the diagnostics market.
Market read
A material M&A transaction in the U.S. healthcare sector that could affect stock valuations of both parties and signal further consolidation.
What to watch
Regulatory approval timeline and integration costs could delay or diminish expected synergies.
Background
The press release details the terms of the asset sale, including cash consideration and earnout tied to the 4Kscore® Test revenue.
Ticker impact
Labcorp agreed to acquire selected BioReference Health assets for $722M cash, subject to regulatory approval.
likely modest upside as the market values the strategic expansion and revenue synergies.
A sizable cash acquisition is a fresh, material event that can boost Labcorp's growth outlook.
Market effects
Strengthens Labcorp's position in clinical and women's health testing, may spur consolidation in the diagnostics sector.
U.S. healthcare services market sees a notable M&A transaction, modest ripple to related biotech service firms.
Limited to U.S. diagnostics industry; no immediate global macro effect.
Counterpoint
The earnout component adds execution risk; investors may view the deal as overpaying for assets.
Key entities
- CompanyOPKO Health, Inc.
Seller of BioReference Health assets.
- CompanyLabcorp
Buyer of the assets.
